Year: 2024
Type: article
Abstract: IntroductionBorderline ovarian tumors (BOT) behave as intermediate lesions between benign cystadenomas and invasive carcinomas, making them separate histologic and clinical entity.They represent 10% to 20% of all epithelial tumors of the ovary.They are characterized by an atypical epithelial cell proliferation without stromal invasion.These tumors are often diagnosed at an early stage while still confined to one or both ovaries, considered as stage I BOT according to the International Federation of Gynecology and Obstetrics (FIGO) classification.BOT of all stages combined have favorable 5-year and 10-year survival rates of 95% and 90%, respectively.Serous borderline tumors often present as complex adnexal masses.Serous borderline tumors more commonly have papillary projections [1,2].
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4407550813